Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)

v3.24.2.u1
Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)
 1 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2024
GBP (£)
Dec. 31, 2023
GBP (£)
Sep. 30, 2023
GBP (£)
Jun. 30, 2023
GBP (£)
Jun. 30, 2024
USD ($)
Jun. 30, 2024
GBP (£)
Dec. 31, 2023
GBP (£)
Apr. 06, 2023
USD ($)
Apr. 06, 2023
GBP (£)
Revenue                  
Revenue recognized in the period         $ 133,011,000        
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements         154,393,000        
GSK Termination and Transfer Agreement                  
Revenue                  
Upfront payment received | £       £ 7,500,000          
Milestone payment | £ £ 6,000,000 £ 12,000,000 £ 3,000,000       £ 12,000,000    
Milestone met and accrued | £           £ 1,500,000      
Amount of transaction price of the agreement at inception               $ 37,335,000  
Upfront and milestone payment receivable | £                 £ 30,000,000
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements         29,878,000        
IGNYTE                  
Revenue                  
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements         13,958,000        
LTFU                  
Revenue                  
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements         $ 15,920,000